Soluble CD40L can promote tumor progression by increasing MDSCs and Tregs in the TME and inhibiting T cell expansion (18–20) and may be a negative prognostic of survival in NSCLC (42).A few recent studies have reported sex-related differences in circulating cytokines in patients treated with immune checkpoint therapy. This evidence concerns the gene CD40LG and neoplasm.